Frederick J. Raal

1994–2025 年に発表

117
論文数
32,528
被引用数
69
h 指数
112
i10 指数

被引用数

Frederick J. Raal の年別被引用数1985 年: 被引用 1 件1991 年: 被引用 3 件1995 年: 被引用 1 件1997 年: 被引用 1 件1998 年: 被引用 1 件1999 年: 被引用 1 件2000 年: 被引用 4 件2001 年: 被引用 3 件2002 年: 被引用 4 件2003 年: 被引用 5 件2004 年: 被引用 5 件2005 年: 被引用 11 件2006 年: 被引用 1 件2007 年: 被引用 6 件2008 年: 被引用 1 件2009 年: 被引用 2 件2010 年: 被引用 5 件2011 年: 被引用 22 件2012 年: 被引用 34 件2013 年: 被引用 76 件2014 年: 被引用 170 件2015 年: 被引用 305 件2016 年: 被引用 439 件2017 年: 被引用 442 件2018 年: 被引用 358 件2019 年: 被引用 1,138 件2020 年: 被引用 1,211 件2021 年: 被引用 1,406 件2022 年: 被引用 1,185 件2023 年: 被引用 1,102 件2024 年: 被引用 1,749 件2025 年: 被引用 942 件2026 年: 被引用 82 件1986〜1990 年は被引用が無いため表示していません1992〜1994 年は被引用が無いため表示していません1996 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,016 件、この内訳の 18.2%中国: 引用元論文 797 件、この内訳の 7.2%イギリス: 引用元論文 784 件、この内訳の 7.1%イタリア: 引用元論文 646 件、この内訳の 5.8%カナダ: 引用元論文 511 件、この内訳の 4.6%ドイツ: 引用元論文 482 件、この内訳の 4.4%オランダ: 引用元論文 450 件、この内訳の 4.1%オーストラリア: 引用元論文 408 件、この内訳の 3.7%フランス: 引用元論文 349 件、この内訳の 3.2%スペイン: 引用元論文 341 件、この内訳の 3.1%ポーランド: 引用元論文 235 件、この内訳の 2.1%スウェーデン: 引用元論文 235 件、この内訳の 2.1%
0%18.2%その他 34.4%

分野

  • Medicine75.4%
  • Biochemistry, Genetics and Molecular Biology16.3%
  • Immunology and Microbiology3.2%
  • Nursing0.8%
  • Neuroscience0.7%
  • Environmental Science0.6%
  • その他3%

トピック

  • Lipoproteins and Cardiovascular Health19%
  • Diabetes, Cardiovascular Risks, and Lipoproteins9.4%
  • Atherosclerosis and Cardiovascular Diseases3.7%
  • Cancer, Lipids, and Metabolism3.6%
  • Lipid metabolism and disorders3.4%
  • Cholesterol and Lipid Metabolism3.1%
  • その他57.8%

共著者

全論文

検索で開く
  1. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2017 被引用: 3,840

  2. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

    著者: , , , , , , , , , , - New England Journal of Medicine 2020 被引用: 1,564

  3. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2020 被引用: 1,527

  4. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

    著者: , , , , , , , , , , - New England Journal of Medicine 2020 被引用: 801

  5. Evinacumab for Homozygous Familial Hypercholesterolemia

    著者: , , , , , , , , , , , , , , , - New England Journal of Medicine 2020 被引用: 764

  6. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

    著者: , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 2,289

  7. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2013 被引用: 2,737

  8. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

    著者: , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2023 被引用: 331

  9. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Georgirene D. Vladutiu, Frederick J. Raal, Kausik K. Ray, Michael Roden, Evan A. Stein, Lâle Tokgözoğlu, Børge G. Nordestgaard, Eric Bruckert, Ronald M. Krauss, Ulrich Laufs, Raul D. Santos, Winfried März, Connie B. Newman, M. John Chapman, Henry N. Ginsberg, M. John Chapman, Henry N. Ginsberg, Guy De Backer, Alberico L. Catapano, Robert A. Hegele, G. Kees Hovingh, Terry A. Jacobson, Lawrence A. Leiter, François Mach, Olov Wiklund - European Heart Journal 2015 被引用: 1,420

  10. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia

    著者: , , , , , , , , , , , , , , , , , , , , , - Nature Reviews Cardiology 2023 被引用: 226

  11. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

    著者: , , , , , , , , , , , , - European Heart Journal 2022 被引用: 214

  12. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

    著者: , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 1,495

  13. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

    著者: , , , , , , , , , , , , - Journal of the American College of Cardiology 2021 被引用: 228

  14. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pablo Corral, Kairat Davletov, Olivier Descamps, Ronen Durst, М. В. Ежов, Dan Gaiță, Jacques Genest, Urh Grošelj, Mariko Harada‐Shiba, Kirsten B. Holven, Meral Kayıkçıoğlu, Weerapan Khovidhunkit, Katarina Lalić, Gustavs Latkovskis, Ulrich Laufs, Evangelos Liberopoulos, Marcos M. Lima-Martínez, Jie Lin, Vincent Maher, Adéle Marais, Winfried März, Erkin М Мirrakhimov, André R. Miserez, Olena Mitchenko, Hapizah Nawawi, Børge G. Nordestgaard, Andrie G. Panayiotou, György Paragh, Žaneta Petrulionienė, Belma Pojskić, Arman Postadzhiyan, Katarı́na Rašlová, Ashraf Reda, Željko Reiner, Fouzia Sadiq, Wilson E. Sadoh, Heribert Schunkert, Aleksandr B. Shek, Mario Stoll, Erik S.G. Stroes, Ta‐Chen Su, Tavintharan Subramaniam, Andrey V. Susekov, Myra Tilney, Brian Tomlinson, Thanh Huong Truong, Alexandros D. Tselepis, Anne Tybjærg‐Hansen, Alejandra Cárdenas, Margus Viigimaa, Luya Wang, Shizuya Yamashita, John J.P. Kastelein, Éric Bruckert, Branislav Vohnout, Laura Schreier, Jing Pang, Christoph Ebenbichler, Hans Dieplinger, Reinhold Innerhofer, Yvonne Winhofer-Stöckl, Susanne Greber‐Platzer, Konstantin A. Krychtiuk, Walter S. Speidl, Hermann Toplak, Kurt Widhalm, Thomas M. Stulnig, Kurt Huber, Florian Höllerl, Gersina Rega‐Kaun ほか 624 名 - The Lancet 2021 被引用: 305

  15. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daisy Rymen, Peter Witters, Raúl D. Santos, Liam R. Brunham, Gordon A. Francis, Jacques Genest, Robert A. Hegele, Brooke A. Kennedy, Isabelle L. Ruel, Mark Sherman, Long Jiang, Luya Wang, Željko Reiner, V. Bláha, R Češka, Jana Dvořáková, Lubomir Dlouhy, Pavel Hořák, Vladimír Soška, Lukáš Tichý, Robin Urbánek, H Vaverková, Michal Vrablı́k, Stanislav Zemek, Lukáš Zlatohlávek, Sameh Emil, Tarek Naguib, Ashraf Reda, Sophie Béliard, Éric Bruckert, Antonio Gallo, Moses Elisaf, Genovefa Kolovou, Hofit Cohen, Ronen Durst, Eldad J. Dann, Avishay Elis, Osama Hussein, Eran Leitersdorf, Daniel Schurr, Nitika Setia, Ishwar C. Verma, Mohammed Alareedh, Mutaz Al-Khnifsawi, Ali Fawzi Abdalsahib Al-Zamili, Sabah H. Rhadi, Foaad Shaghee, Marcello Arca, Maurizio Averna, Andrea Bartuli, Marco Bucci, Paola Sabrina Buonuomo, Paolo Calabrò, S. Calandra, Manuela Casula, Alberico L. Catapano, Angelo B. Cefalù, Arrigo F.G. Cicero, Sergio D’Addato, Laura D’Erasmo, Alessia Di Costanzo, Tommaso Fasano, Marta Gazzotti, Antonina Giammanco, Gabriella Iannuzzo, Anastasia Ibba, Emanuele Alberto Negri, Andrea Pasta, Chiara Pavanello, Livia Pisciotta ほか 73 名 - The Lancet 2022 被引用: 207

  16. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

    著者: , , , , , , , , , , , , , , , , , - The Lancet 2014 被引用: 751

  17. The Agenda for Familial Hypercholesterolemia

    著者: , , , , , , , , , , , , - Circulation 2015 被引用: 727

  18. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

    著者: , , , , , , , , , , - European Heart Journal 2022 被引用: 111

  19. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anne Tybjærg‐Hansen, Olov Wiklund - European Heart Journal 2015 被引用: 870

  20. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2018 被引用: 381

  21. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

    著者: , , , , , , , - The Lancet 2014 被引用: 727

  22. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

    著者: , , , , , , , , , , , , - The Lancet 2010 被引用: 906

  23. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial

    著者: , , , , , , , - Circulation 2023 被引用: 82

  24. Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Vimal Mehta, Raman Puri, Ashwani Mehta, Preeti Gupta, Milan Chag, Akshyaya Pradhan, Francisco Fuentes Jimenez, Fernando Civeira Murillo, Xavier Pinto Sala, Russell Scott - European Heart Journal 2023 被引用: 67